Heart failure & cardiomyopathiesSecondary analysis
Age, Sex, and Outcomes in Heart Failure With Reduced EF
- Secondary analysis of the VICTORIA randomised trial
- post hoc analysis
Authors' conclusion
Although elderly women received less intense background HF therapy than men, their prognosis was nominally better. The benefit of vericiguat was independent of age and sex.
Study context
- Population
- Patients with heart failure (HF) and reduced EF in VICTORIA
- Participants
- 5,050 patients
- Comparison
- Vericiguat treatment effect by age and sex
- ≥75 yearsn = 1,568
- Primary endpoint
- Time to first HF hospitalization or CV death
Primary result
As reported in the abstract
Vericiguat effect on primary composite outcome, by age and sex
Benefit not modified by continuous age
Pinteraction = 0.169
Benefit not modified by categorical age
Pinteraction = 0.189
Benefit not modified by sex (3-way interaction)
P = 0.847
Further findings
Clinical characteristics and therapy by age and sex
- ≥75 years: more class III–IV symptoms, higher NT-proBNP, worse kidney function, lowest use of triple therapy
- No sex differences in triple therapy by age; target doses less likely in older patients
- Men ≥75 years more than twice as likely to receive defibrillators and 65% more likely to undergo cardiac resynchronization than women
- Primary composite outcome nominally lower in women than men across all age groups
- Vericiguat dosing did not differ between sexes in each age group
Original publication
Age, Sex, and Outcomes in Heart Failure With Reduced EF. JACC Heart Fail. Published 9 August 2023. doi:10.1016/j.jchf.2023.06.020
Summarised from the published abstract; every number is checked against it